12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Company News  |  Deals

Apricus Biosciences, PediatRx Inc. deal

The companies signed a non-binding term sheet for Apricus to acquire PediatRx for about $4 million in stock and the assumption of $675,000 of PediatRx's debt. The deal is subject to approval by both companies boards.

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >